The present meta-analysis compared the efficacy and toxicity between idarubicin (IDA) and high-dose daunorubicin (HDD) for induction therapy for adult acute myeloid leukemia (AML). Across the 5 included studies, patients who had received IDA had a significantly greater complete remission rate after first induction therapy and lower rate of refractory AML after induction therapy compared with those who received had HDD. Background: The 2 main formulations of anthracycline used for acute myeloid leukemia (AML) induction therapy are idarubicin (IDA) and daunorubicin. Patients and Methods: The present systematic review and meta-analysis compared the efficacy and toxicity between IDA and high-dose daunorubicin (HDD) for induction therapy for adult AML. Relevant studies reported before June 2018 were searched from the Medline and Embase databases. Results: A total of 5 studies with 1809 participants (3 randomized controlled studies and 2 retrospective cohort studies) met the eligibility criteria and were included in the meta-analysis. The patients in the IDA arm for induction therapy had a significantly greater complete response rate after the first course of induction therapy compared with those in the HDD arm (66.7% vs. 61.1%, respectively; odds ratio, 1.23; P ¼ .04; I 2 ¼ 0%). A significantly lower rate of refractory AML was also observed in the IDA group than in the HDD group (16.8% vs. 20.7%, respectively; odds ratio, 0.77; P ¼ .04; I 2 ¼ 0%). However, no difference was found in the long-term overall survival between the 2 groups. Also, the induction mortality rate, febrile neutropenia rate, and cardiotoxicity rate were not significantly different between the 2 groups. The major limitation was the relatively small number of included studies, which could have limited the power of the meta-analysis to demonstrate significant long-term benefits. Conclusion: The complete response rate after the first course of induction therapy was significantly greater among adult patients with AML who had received IDA as part of induction therapy compared with those who had received HDD.
Introduction
Acute myeloid leukemia (AML) is the most common acute leukemia in adults. From 2001 to 2013, 32,941 cases of adult AML were registered in the Surveillance, Epidemiology, and End Results database. 1 The median patient age was 62 years (range, 47-74), with slight male predominance. 1 Patients with AML usually present with symptoms of bone marrow failure, including anemia symptoms, fever, and bleeding abnormalities. The current most effective initial therapeutic option is an anthracycline combined with standard-dose cytarabine (7þ3 regimen). The regimen consists of 7 days of 100 to 200 mg/m 2 /d of cytarabine plus 3 days of an anthracycline. A high 1 Division of Hematology, Department of Medicine complete response (CR) rate was reported for patients aged 60 years after induction therapy, with a CR rate of 60% to 85%. 2 The 2 main formulations of anthracycline used for AML induction therapy are idarubicin (IDA) and daunorubicin. Wide dose ranges of daunorubicin were used in previous studies, ranging from 45 to 90 mg/m 2 /d. In contrast, IDA was commonly used at the dose of 12 mg/m 2 /d. 3 Several randomized controlled trials have reported a greater CR rate and a lower relapse rate in patients initially treated with high-dose daunorubicin (HDD) compared with patients who had received standard-dose daunorubicin (SDD). [4] [5] [6] Accordingly, the European LeukemiaNet research network has recommended a dose > 60 mg/m 2 /d. 3 Two current standard guidelines from the European LeukemiaNet and the National Comprehensive Cancer Network have still suggested that either HDD or IDA can be used for AML induction therapy. 3, 7 Several randomized controlled trials have compared the efficacy of these 2 different regimens for AML induction therapy. However, the results were inconsistent, 4, 5, [8] [9] [10] and some studies also used SDD, which is known to be inferior to HDD. A meta-analysis reported in 2015 attempted to compare the efficacy of HDD versus IDA for induction therapy for AML and could not find a statistically significant difference between the 2 regimens in terms of the CR rate, event-free survival (EFS), or overall survival (OS).
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However, only 3 studies of adults and a pediatric study were included in that meta-analysis. Since then, more data have been reported; thus, the present systematic review and meta-analysis was conducted with the aim of identifying all available studies and summarizing the results of those studies to compare the efficacy and toxicity of IDA and HDD for induction chemotherapy for adults with AML.
Patients and Methods
The need for ethics approval by the institutional board review was waived because the present study did not directly involve human subjects.
Data Sources and Searches
Three of us (W.O., N.O., and S.M.) independently searched reported studies indexed in the Medline and Embase databases from inception to June 1, 2018 using a search strategy that included the terms for AML and the names of the chemotherapy agents. The search strategy is provided in Supplemental Appendix 1 (available in the online version). The references of the included studies were also manually reviewed for additional eligible studies. The present study was undertaken in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement (Supplemental Figure 1 ; available in the online version). 12 
Selection Criteria and Data Extraction
The studies considered eligible for the present meta-analysis were randomized controlled studies or cohort studies (either prospective or retrospective) that had compared the efficacy of IDA and HDD as induction chemotherapy for adult AML. They were also required to have reported our primary outcome of interest, the CR rate after the first course of induction therapy (CRF). HDD was defined as a dose of daunorubicin > 60 mg/m 2 /d or a cumulative dose of daunorubicin > 180 mg/m 2 /course. 3 The secondary outcomes of interest, including the overall CR rate, refractory AML rate, rate of febrile neutropenia after induction therapy, induction mortality rate, cardiotoxicity rate, OS, EFS, and cumulative incidence of relapse, were also collected for analysis. However, they were not required as inclusion criteria. The assessment of eligibility for each study was independently conducted by 3 of us (W.O., N.O., and S.M.). In the case of different decisions regarding study eligibility, the studies in question were reviewed together by the same 3 investigators (W.O., N.O., and S.M.), and the final determination was reached by mutual consensus.
Outcome Definitions
A CR was defined as the presence of < 5% bone marrow blasts, the absence of circulating blasts and blasts with Auer rods, the absence of extramedullary disease, an absolute neutrophil count (ANC) ! 1.0 Â 10 9 /L, and a platelet count of ! 100 Â 10 9 /L. 3 The overall CR was defined as the sum of the CR rates from each course of induction therapy. Refractory AML was defined as failure to achieve a CR after 2 courses of induction therapy. Induction mortality was defined as death occurring during hospital admission for induction therapy. After induction therapy, ANC recovery was defined as an ANC of ! 0.5 Â 10 9 /L, and platelet recovery was defined as a platelet count of ! 20 Â 10 9 /L. OS was defined as the interval between the diagnosis and the date of death or last follow-up examination. EFS was defined as the interval from the date of diagnosis to the date of induction therapy failure, relapse, or death from any cause. Relapse was estimated for the patients who had achieved a CR using a cumulative incidence function with respect to competing risks.
Quality Assessment
The quality of the included studies was evaluated using the Jadad quality assessment scale for randomized controlled studies. 13 The
Newcastle-Ottawa scale is a 3-item scoring system that includes participant selection, comparability between groups, and ascertainment of exposure for case-control studies and the outcome of interest for cohort studies. The scale was used to assess the quality of the nonrandomized studies. 14 
Statistical Analysis
All statistical analyses were performed using Review Manager, version 5.3, software (Cochrane Collaboration, London, United Kingdom). We extracted the effect estimates and 95% confidence intervals from each study and pooled them using the MantelHaenszel method. 15 The Cochran Q test was used, and the I 2 statistic was quantified to evaluate the statistical heterogeneity among the included studies. The I 2 values were categorized as follows: 0% to 25%, insignificant heterogeneity; 26% to 50%, low heterogeneity; > 50% to 75% indicated moderate heterogeneity; and > 75%, high heterogeneity. 16 A random effects model, rather than a fixed effects model, was used because of the high likelihood of between-study heterogeneity. Funnel plots and Egger's test were not used to evaluate for publication bias owing to the small number of included studies (<10 studies). P values < .05 were considered to indicate statistical significance.
Results
The described search strategy yielded 2272 potentially relevant reports (148 from Medline and 2124 from Embase). After exclusion of 1016 duplicate reports, the remaining 1256 were evaluated for relevance by a review of the title and abstract. Of those, 1242 studies were excluded. The exclusion criteria were as follows: (1) reported in a language other than English; (2) a review or meta-analysis, commentary, editorial, or conference abstract; (3) reports irrelevant to AML; (4) reports that had included pediatric patients (age < 15 years); (5) reports irrelevant to a comparison between HDD and IDA; and/or (6) reports without primary endpoints. The remaining 14 studies underwent a full-length review. Of those, 9 were excluded because of similar reasons to those found in the first evaluation. Finally, 5 studies (3 randomized controlled studies and 2 retrospective cohort studies) met the eligibility criteria and were included in the meta-analysis. 10, [17] [18] [19] [20] The literature review process is summarized in Figure 1 . The baseline characteristics, including white blood cell (WBC) count, cytogenetic risk, molecular mutational status, anthracycline dose, country, study period, article type, and quality assessment score, for each study are listed in Table 1 .
Baseline Patient Characteristics
A total of 1809 patients were included in the present metaanalysis (912 patients in the HDD arm and 897 patients in the IDA arm). The age range in the HDD group was 15 to 72 years, and the range in the IDA group was 17 to 73 years. Approximately one half of patients in both groups were men. The patients' performance status using the Eastern Cooperative Oncology Group classification system was > 2 for 3.2% of the patients in both treatment arms, which was reported by 2 studies. 10, 17 Another study reported the Karnofsky performance scale scores. Excluded (n=1,242) 1) Reports in languages other than English 2) Reviews or meta-analyses, commentaries, editorials, or conference abstracts 3) Reports irrelevant to AML 4) Reports including patient age <15 years 5) Reports irrelevant to comparison between HDD and IDA 6) Reports have no primary endpoints Excluded (n=9) 1) Reviews or meta-analyses 2) Reports including patient age <15 years 3) Reports irrelevant to comparison between HDD and IDA Abbreviations: HDD ¼ high-dose daunorubicin; IDA ¼ idarubicin. administered 12 mg/m 2 of IDA on days 1 to 3; however, a 2-arm trial had included 1 arm with 4 days of IDA. 17 The latter arm was excluded from our meta-analysis because a 4-day IDA protocol is not the standard recommendation. In the HDD arm, some variation was found in the dose and duration of daunorubicin across the studies. One study administered daunorubicin on days 1 to 5 at a dose of 50 mg/m 2 /d. 10 The patients in 3 studies received 90 mg/ m 2 /d of daunorubicin on days 1 to 3. [18] [19] [20] The patients in 1 study received 80 mg/m 2 /d of daunorubicin on days 1 to 3. 17 One study also had an SDD arm; however, this arm was not included in our meta-analysis. 20 
Response to Induction Therapy
The patients who received IDA had a significantly greater CRF rate compared with the patients who had received HDD (66.7% vs. 61.1%, respectively; odds ratio [OR], 1.23; 95% confidence interval [CI], 1.01-1.49; P ¼ .04; I 2 ¼ 0%; Figure 2A) . 10, [17] [18] [19] [20] Additionally, the overall CR rate in the IDA group was numerically greater than that in the HDD group, although the difference did not reach statistical significance (79% vs. 76%, respectively; OR, 1.22; 95% CI, 0.89-1.69; P ¼ .22; I 2 ¼ 34%; Figure 2B ). 10, [17] [18] [19] [20] The rate of refractory AML was significantly lower in the IDA group than in the HDD group (16.8% vs. 20.7%, respectively; OR, 0.77; 95% CI, 0.61-0.99; P ¼ .04; I 2 ¼ 0%; Figure 2C ).
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Long-term Outcomes
Long-term OS was reported by 4 studies (4-year follow-up OS in 2 studies 17, 19 and 5-year OS in 2 studies 10, 20 ). The long-term OS rates were quite similar between the IDA and HDD groups (45.2% vs. 44.8%, respectively; OR, 1.02; 95% CI, 0.76-1.36; P ¼ .92; I 2 ¼ 40%; Figure 3A) . 10, 17, 19, 20 Likewise, the EFS rates were similar between the 2 groups (32.9% in the IDA vs. 31.7% in the HDD group; OR, 1.11; 95% CI, 0.59-2.06; P ¼ .75; I 2 ¼ 64%; Figure 3B ), 17, 19, 20 with a similar cumulative incidence of relapse Figure 3C ).
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Treatment Complications
The incidence of febrile neutropenia was similar in both groups (77.4% in the IDA vs. 77.3% in the HDD group; OR, 1.0; 95% CI, 0.78-1.29; P ¼ .98; I 2 ¼ 0%; Figure 4A ). 10, 19 The induction mortality rate was also not significantly different between the 2 groups (4.8% in the IDA vs. 3.3% in the HDD group; OR, 1.59; 95% CI, 0.49-5.12; P ¼ .44; I 2 ¼ 66%; Figure 4B ). 10, 17, 18, 20 Also, no statistically significant difference was found in the incidence of cardiotoxicity (1.8% in the IDA vs. 1.1% in the HDD group; OR, 1.77; 95% CI, 0.70-4.49; P ¼ .23; I 2 ¼ 0%; Figure 4C ).
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Subgroup Analysis
The clinical outcomes stratified by age group, AML type (de novo AML vs. secondary AML), cytogenetic risk, and molecular mutational status, were provided by few of the included studies and are summarized in Supplemental Table 1 (available in the online version). Because the number of studies that provided the information was too small, meta-analyses of these subgroups could not be conducted.
Discussion
To the best of our knowledge, the present study is the first systematic review and meta-analysis to compare the efficacy and toxicity of IDA and HDD for induction chemotherapy in adults with AML. A total of 5 studies from France, the United States, Japan, and South Korea were identified and included in the present meta-analysis. The number of participants in both arms was similar and the baseline characteristics of the participants in each group were also similar, including age, sex, performance status, and a high WBC count. Across the included studies, we found that patients who had received IDA as a part of their 7þ3 regimen had a significantly greater chance of achieving a CR after the first induction therapy compared with those who had received HDD. The rate of refractory AML after induction therapy was also lower among those treated with IDA. This observation could have important clinical implications because the patients without a CR after induction therapy had shorter long-term survival than those patients with a CR. 22 A study from in 2016 reported a significantly greater 2-year OS rate among patients with a CR compared with those without a CR (53.3% vs. 28.3%, respectively).
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The findings from the present meta-analysis failed find a superior long-term benefit with, because the long-term OS and EFS rates were similar to those for the HDD group. Nonetheless, it is generally more difficult to attribute long-term outcomes to the initial treatment alone, because subsequent treatment can also have a significant effect. For example, 2 studies included in the present meta-analysis switched the second course of induction therapy to other regimens after an incomplete response to the first course of induction therapy. 17, 18 The rate of allogeneic stem cell transplantation after a CR can also vary. Therefore, we believe that the CRF should be the main focus of analyses comparing the efficacy of IDA versus HDD. IDA did not appear to increase the incidence of complications, with a similar rate of febrile neutropenia and cardiotoxicity. The induction mortality rate was numerically greater among IDA group; however, the difference was not statistically significant.
The main limitation of the present study was the relatively limited number of studies included in the meta-analysis. Although we had sufficient power to demonstrate statistical significance for our primary outcome (ie, CRF), several secondary analyses showed nonsignificant results, which might be suggestive of inadequate power. This could be the explanation for why we could not demonstrate a significant long-term survival benefit despite the greater CRF rate for the patients who received IDA. The small number of included studies also prohibited us from conducting an assessment for publication bias.
Conclusion
The rate of CRF was significantly greater among adult patients with AML who had received IDA as part of induction therapy compared with those who had received HDD. The rate of toxicity related to treatment appears to be similar for the 2 regimens.
Clinical Practice Points
Current standard guidelines still suggest that either HDD or IDA can be used for AML induction therapy. A total of 1809 patients were included in the present metaanalysis (912 patients in the HDD arm and 897 in the IDA arm) to compare the efficacy and toxicity between 2 groups. Patients who had received IDA as part of their 7þ3 regimen had a significantly greater chance of achieving CR after the first induction therapy than those who had received HDD. 
IDA Versus HDD for Adult AML
The rate of refractory AML after induction therapy was lower among those who had received with IDA. The induction mortality rate, rate of febrile neutropenia, and cardiotoxicity rate were similar between the 2 groups. No significant long-term survival benefit was found in the IDA group owing to the relatively small number of included studies.
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